Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Repligen Corporation Common Stock (RGEN) vs T-Mobile Us Inc (TMUS) Price & Performance

Repligen Corporation Common StockTrade
T-Mobile Us IncTrade

Price performance (Past 24H)

Key statistics

Repligen Corporation Common Stock vs T-Mobile Us Inc — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while T-Mobile Us Inc trades at $158.49 (market cap $164.91B). The key difference: T-Mobile Us Inc is far larger — about 14.8× Repligen Corporation Common Stock's market cap, and T-Mobile Us Inc pays a 3.04% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and T-Mobile Us Inc for 84 Days on average.

RGENTMUS
Market Cap
$11.14B$164.91B
Volume
1,259,2635,684,850
Sector
HealthMedia
52-Week High
$194.57$230.06
52-Week Low
$102.87$148.58
Typical Hold Time
0 Days84 Days
Enterprise Value
$11.02B$281.53B
Dividend Yield
—3.04%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Repligen Corporation Common Stock

RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.

Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.

T-Mobile Us Inc

T-Mobile US (TMUS) trades at $157.79, up 3.9% with strong recent earnings beats but faces technical bearish signals. The company maintains robust fundamentals with $88.31B revenue (2025), 11.45% net margin, and attractive valuation ratios (P/E 16.08, EV/EBITDA 8.73). Recent developments include a 15% dividend hike and AI-powered 5G network enhancements, though debt levels remain elevated at $84.6B.

TMUS presents a compelling growth story with solid profitability and analyst support (81% buy rating, $221.75 target), but investors must weigh technical weakness against fundamental strength. Key risks include competitive pressures, macroeconomic uncertainty, and the company's substantial debt load in a rising rate environment.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

RGEN
100% Buy0% Sell
Avg holding period · 0 Days
TMUS
96% Buy4% Sell
Avg holding period · 84 Days

Top news

Latest headlines on both assets

About Repligen Corporation Common Stock

Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.

Read more on RGEN →

About T-Mobile Us Inc

Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.

Read more on TMUS →